ClinicalTrials.gg
RecruitingNCT01366404IRIS FFRUpdated Mar 20, 2026

Study of the Natural History of FFR Guided Percutaneous Coronary Intervention

An observational study in Coronary Artery Disease, sponsored by Seung-Jung Park. Recruiting at 29 sites in South Korea. Open to participants aged 35 Years and older. Per ClinicalTrials.gov, last updated 2026-03-20.

Sponsored by Seung-Jung Park · Observational

How we know

From the registry’s dates

  • Started Jun 2011; still recruiting 15 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
20,000
Ages
35 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 59 studies in Coronary Artery Disease by Seung-Jung Park — 11 open to participants now, 13 under way, none of them phase 3. Coronary Artery Disease · Seung-Jung Park.

Planned enrollment
4th of 30
20,000 · median 2,000
Started
2011
with 4 others
Observational
30 of 59
10 open now
Primary completion
2037-04
later than 12 of 12 live
Registered
32nd of 59
by date

Among the 59 studies in Coronary Artery Disease by Seung-Jung Park, this one is the 4th largest by planned enrollment of the 30 observational ones that give a count, is one of 5 that started in 2011, is one of 30 observational ones, reaches primary completion later than 12 of the 12 other live ones, and was the 32nd registered.

Coronary Artery Disease

4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.

Browse Coronary Artery Disease studies →

Open to participants now

11 of the 59 studies in Coronary Artery Disease by Seung-Jung Park are open now, in 8 countries. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 11 open studies →

Who these studies take

Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.

This study: 35 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 59 studies in Coronary Artery Disease by Seung-Jung Park, or all of them as a file.
02

Study summary

About 20,000 patients with FFR (Fractional Flow Reserve) will be enrolled and evaluated for the natural history of coronary lesions at 2 years clinical and imaging follow-up.

Read the detailed description

This is a multicenter, prospective cohort. About 20,000 patients with FFR will be enrolled at multi centres in Korea.

03

Conditions studied

  • Coronary Artery Disease

Keywords

  • FFR
04

Who can participate

Ages eligible
35 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients who had FFR measurement

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 35 years and older
  • FFR measurement on one and more coronary artery stenosis
  • Willing and able to provide informed, written consent

Exclusion criteria

Exclusion Criteria:

  • Stenosis with TIMI\<3 flow
  • Graft vessel
  • \< 30%
  • Angiographic evidence of extreme tortuosity or calcified coronary vessels
  • Suspected coronary spasm even after sufficient nitrate injected
  • \<2 year
  • Planned cardiac surgery or planned major non cardiac surgery
  • Woman who are breastfeeding, pregnant or planning to become pregnant during the course of the study

Imaging study specific exclusion criteria

  • visually-estimated angiographic reference segment diameter of \<2.75mm or >4.0mm
  • Inappropriate for IVUS/VH/OCT procedures : inability for imaging wire or catheter to pass through the tight stenosis, severe calcification, angulation
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
20,000 participants (estimated)
Patient registry
No

Groups and cohorts

  • FFR

    Patients who had FFR measurement

06

What researchers measure

Primary outcomes

  1. Target vessel failure

    Time frame: 2 year after index FFR measurement

  2. composite Cardiac Death,Non Fatal Myocardial Infarction, Target Vessel Revascularization, and Indeterminate events

    Time frame: at 2 year after index FFR measurement

Secondary outcomes

  1. Death (all cause and cardiac)

    Time frame: at 2 year after index FFR measurement

  2. MI

    Time frame: at 2 year after index FFR measurement

  3. Target vessel revascularization

    Time frame: at 2 year after index FFR measurement

  4. Target lesion revascularization

    Time frame: at 2 year after index FFR measurement

  5. Any re-hospitalization with a cardiac cause

    Time frame: 2 year follow-up after index FFR measurement

  6. cardiac death and myocardial infarction

    Time frame: 2 year follow-up after index FFR measurement

  7. stented lesion related event including death, myocardial infarction, repeat revascularization

    Time frame: 2 year follow-up after index FFR measurement

  8. stroke

    Time frame: 2 year follow-up after index FFR measurement

  9. stent thrombosis

    Time frame: 2 year follow-up after index FFR measurement

  10. anginal status

    Time frame: 2 year follow-up after index FFR measurement

  11. number of anti-anginal medication prescribed

    Time frame: 2 year follow-up after index FFR measurement

  12. complication of FFR measurement

    Time frame: 2 year follow-up after index FFR measurement

  13. clinical predictors of events

    Time frame: 2 year follow-up after index FFR measurement

  14. change in plaque composition (%necrotic core volume) in target segment

    Time frame: 2 year follow-up after index FFR measurement

  15. change in plaque type assessed by VH(Virtual Histology) and OCT(Optical coherence tomography)

    Time frame: 2 year follow-up after index FFR measurement

  16. change in total atheroma volume and percent atheroma volume

    Time frame: 2 year follow-up after index FFR measurement

  17. change in IVUS-measured MLA

    Time frame: 2 year follow-up after index FFR measurement

  18. change in FFR

    Time frame: 2 year follow-up after index FFR measurement

07

Study locations

29 of 29 sites recruiting
  • Hallym University Sacred Heart Hospital
    Anyang, South Korea
    Recruiting
    • Hyun-sook Kim, MD · Contact
    • Hyun-sook Kim, MD · Principal investigator
  • Soon Chun Hyang University Hospital Bucheon
    Bucheon-si, South Korea
    Recruiting
    • Nae-hee Lee, MD · Contact
    • Nae-hee Lee, MD · Principal investigator
  • Chungbuk National University Hospital
    Cheongju-si, South Korea
    Recruiting
    • Sang-yeub Lee, MD · Contact
    • Sang-yeub Lee, MD · Principal investigator
  • Gangwon National Univ. Hospital
    Chuncheon, South Korea
    Recruiting
    • Bong-ki Lee, MD · Contact
    • Bong-ki Kim, MD · Principal investigator
  • Daegu Catholic University Center
    Daegu, South Korea
    Recruiting
    • Jin-bae Lee, MD · Contact
    • Jin-bae Lee, MD · Principal investigator
  • Keimyung University Dongsan Medical Center
    Daegu, South Korea
    Recruiting
    • Chang-wook Nam, MD · Contact
    • Chang-wook Nam, MD · Principal investigator
  • Kyungpook National university hospital
    Daegu, South Korea
    Recruiting
    • Hun-sik Park, MD · Contact
    • Hun-sik Park, MD · Principal investigator
  • Yeungnam University Medical Center
    Daegu, South Korea
    Recruiting
    • Jong-seon Park, MD · Contact
    • Jong-seon Park, MD · Principal investigator
  • Chungnam National University Hospital
    Daejeon, South Korea
    Recruiting
    • Si-wan Choi, MD · Contact
    • Si-wan Choi, MD · Principal investigator
  • The Catholic University of Korea, Deajeon St.Mary's hospital
    Daejeon, South Korea
    Recruiting
    • Sung-ho Her, MD · Contact
    • Sung-ho Her, MD · Principal investigator
  • Gangneung Asan Hospital
    Gangneung, South Korea
    Recruiting
    • Sang-sig Jung, MD · Contact
    • Sang-sig Jung, MD · Principal investigator
  • Chonnam National University Hospital
    Gwangju, South Korea
    Recruiting
    • Young-jun Hong, MD · Contact
    • Young-jun Hong, MD · Principal investigator
  • Inje University Ilsan Paik Hospital
    Ilsan, South Korea
    Recruiting
    • Joon-hyung Doh, MD · Contact
    • Joon-hyung Doh, MD · Principal investigator
  • Dong-A Medical Center
    Pusan, South Korea
    Recruiting
    • Kyung-il Park, MD · Contact
    • Kyung-il Park, MD · Principal investigator
  • Pusan National University Hospital
    Pusan, South Korea
    Recruiting
    • Taeg-jong Hong, MD · Contact
    • Taeg-jong Hong, MD · Principal investigator
  • Seoul university Bundang hospital
    Seongnam, South Korea
    Recruiting
    • In-ho Chae, MD · Contact
    • In-ho Chae, MD · Principal investigator
  • Asan Medical Center
    Seoul, South Korea
    Recruiting
    • Seung-jung Park, MD · Contactsjpark@amc.seoul.kr
    • Seung-jung Park, MD · Principal investigator
  • Gangnam Severance Hospital
    Seoul, South Korea
    Recruiting
    • Byoung-kwon Lee, MD · Contact
    • Byoung-kwon Lee, MD · Principal investigator
  • Hallym University Kangdong Sacred Heart Hospital
    Seoul, South Korea
    Recruiting
    • Kyoo-rok Han, MD · Contact
    • Kyoo-rok Han, MD · Principal investigator
  • Korea University Anam Hospital
    Seoul, South Korea
    Recruiting
    • Do-sun Lim, MD · Contact
    • Do-sun Lim, MD · Principal investigator
  • Korea University Guro Hospital
    Seoul, South Korea
    Recruiting
    • Seung-un Na, MD · Contact
    • Seung-un Na, MD · Principal investigator
  • Kyung-Hee University Hospital at Kangdong
    Seoul, South Korea
    Recruiting
    • Jong-jin Kim, MD · Contact
    • Jong-jin Kim, MD · Principal investigator
  • Seoul National University Boramae Medical Center
    Seoul, South Korea
    Recruiting
    • Woo-young Chung, MD · Contact
    • Woo-young Chung, MD · Principal investigator
  • Seoul National University Hospital
    Seoul, South Korea
    Recruiting
    • Bon-kwon Koo, MD · Contact
    • Bon-kwon Koo, MD · Principal investigator
  • The Catholic University of Korea, Seoul St.Mary's Hospital
    Seoul, South Korea
    Recruiting
    • Ki-bae Seung, MD · Contact
    • Ki-bae Seung, MD · Principal investigator
  • The Catholic University of Korea, Yeouido St. Mary's Hospital
    Seoul, South Korea
    Recruiting
    • Chul-soo Park, MD · Contact
    • Chul-soo Park, MD · Principal investigator
  • Ulsan University Hospital
    Ulsan, South Korea
    Recruiting
    • Eun-seok Shin, MD · Contact
    • Eun-seok Shin, MD · Principal investigator
  • Wonju Severance Christian Hospital
    Wŏnju, South Korea
    Recruiting
    • Jung-han Yoon, MD · Contact
    • Jung-han Yoon, MD · Principal investigator
  • Pusan National University Yangsan Hospital
    Yangsan, South Korea
    Recruiting
    • Jun-hong Kim, MD · Contact
    • Jun-hong Kim, MD · Principal investigator
08

References and documents

Publications

  • Ahn JM, Park DW, Kim SO, Kang DY, Lee CH, Lee PH, Lee SW, Park SW, Park SJ. Prognostic Value of Resting Distal-to-Aortic Coronary Pressure in Clinical Practice. Circ Cardiovasc Interv. 2020 May;13(5):e007868. doi: 10.1161/CIRCINTERVENTIONS.118.007868. Epub 2020 Apr 29. PubMed 32345039 ↗
  • Kang DY, Ahn JM, Kim YW, Moon JY, Lee JS, Koo BK, Lee PH, Park DW, Kang SJ, Lee SW, Kim YH, Park SW, Park SJ. Impact of Coronary Lesion Geometry on Fractional Flow Reserve: Data From Interventional Cardiology Research In-Cooperation Society-Fractional Flow Reserve and Intravascular Ultrasound Registry. Circ Cardiovasc Imaging. 2018 Jun;11(6):e007087. doi: 10.1161/CIRCIMAGING.117.007087. PubMed 29895713 ↗
  • Kang DY, Ahn JM, Lee CH, Lee PH, Park DW, Kang SJ, Lee SW, Kim YH, Lee CW, Park SW, Park SJ. Deferred vs. performed revascularization for coronary stenosis with grey-zone fractional flow reserve values: data from the IRIS-FFR registry. Eur Heart J. 2018 May 7;39(18):1610-1619. doi: 10.1093/eurheartj/ehy079. PubMed 29529177 ↗
  • Lee JM, Hwang D, Park J, Zhang J, Tong Y, Kim CH, Bang JI, Suh M, Paeng JC, Cheon GJ, Koo BK. Exploring Coronary Circulatory Response to Stenosis and Its Association With Invasive Physiologic Indexes Using Absolute Myocardial Blood Flow and Coronary Pressure. Circulation. 2017 Nov 7;136(19):1798-1808. doi: 10.1161/CIRCULATIONAHA.117.029911. Epub 2017 Aug 29. PubMed 28851731 ↗
  • Ahn JM, Park DW, Shin ES, Koo BK, Nam CW, Doh JH, Kim JH, Chae IH, Yoon JH, Her SH, Seung KB, Chung WY, Yoo SY, Lee JB, Choi SW, Park K, Hong TJ, Lee SY, Han M, Lee PH, Kang SJ, Lee SW, Kim YH, Lee CW, Park SW, Park SJ; IRIS-FFR Investigatorsdagger. Fractional Flow Reserve and Cardiac Events in Coronary Artery Disease: Data From a Prospective IRIS-FFR Registry (Interventional Cardiology Research Incooperation Society Fractional Flow Reserve). Circulation. 2017 Jun 6;135(23):2241-2251. doi: 10.1161/CIRCULATIONAHA.116.024433. Epub 2017 Mar 29. PubMed 28356440 ↗
  • Lee JM, Kim CH, Koo BK, Hwang D, Park J, Zhang J, Tong Y, Jeon KH, Bang JI, Suh M, Paeng JC, Cheon GJ, Na SH, Ahn JM, Park SJ, Kim HS. Integrated Myocardial Perfusion Imaging Diagnostics Improve Detection of Functionally Significant Coronary Artery Stenosis by 13N-ammonia Positron Emission Tomography. Circ Cardiovasc Imaging. 2016 Sep;9(9):e004768. doi: 10.1161/CIRCIMAGING.116.004768. PubMed 27609817 ↗
  • Kang SJ, Ahn JM, Han S, Lee JY, Kim WJ, Park DW, Lee SW, Kim YH, Lee CW, Park SW, Mintz GS, Park SJ. Sex differences in the visual-functional mismatch between coronary angiography or intravascular ultrasound versus fractional flow reserve. JACC Cardiovasc Interv. 2013 Jun;6(6):562-8. doi: 10.1016/j.jcin.2013.02.016. PubMed 23787231 ↗
  • Park SJ, Kang SJ, Ahn JM, Shim EB, Kim YT, Yun SC, Song H, Lee JY, Kim WJ, Park DW, Lee SW, Kim YH, Lee CW, Mintz GS, Park SW. Visual-functional mismatch between coronary angiography and fractional flow reserve. JACC Cardiovasc Interv. 2012 Oct;5(10):1029-36. doi: 10.1016/j.jcin.2012.07.007. PubMed 23078732 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2011 (actual). Primary completion is estimated for Apr 2037, 310 months after the start.

Of 637 non-industry observational studies under Coronary Artery Disease, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 122. This study's planned 310 months is above that.

Counting every sponsor, half of 762 studies reached it within 41 months; a quarter within 21 and three quarters within 87.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 2, 2011
First posted
Jun 6, 2011
StartActual
Jun 2011
Primary completionEst.
Apr 2037
CompletionEst.
Apr 2037
Last update
Mar 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01366404
Lead sponsor
Seung-Jung Park
Collaborators
CardioVascular Research Foundation, Korea, Abbott Medical Devices
Responsible party
Seung-Jung Park (Professor, Division of Cardiology, CardioVascular Research Foundation, Korea) — Sponsor-investigator
First posted
Jun 6, 2011
Start date
Jun 2011
Primary completion
Apr 2037 (estimated)
Completion
Apr 2037 (estimated)
Last update
Mar 20, 2026

Study contacts

Seung-Jung Park, MD, PhD
Contact
sjpark@amc.seoul.kr
Jung-min Ahn, MD
Contact
drjmahn@gmail.com
Seung-Jung Park, MD,PhD
principal investigator · Asan Medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion